REDWOOD CITY, Calif.,
Feb. 7, 2017 /PRNewswire/
-- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a
specialty pharmaceutical company focused on the development and
commercialization of innovative therapies for the treatment of
moderate-to-severe acute pain, today announced that Timothy E. Morris, Chief Financial Officer, Head
of Business Development will be presenting at the BIO CEO &
Investor Conference, 2017 Disruptive Growth & Healthcare
Conference, Small Cap Nation Family Office & Life Science
Symposium and the RBC Capital Markets 2017 Global Healthcare
Conference. Details of the events are as follows:
BIO CEO & Investor Conference
Date: Tuesday, February 14th
Location: Waldorf Astoria New York
Presentation Time: 9:30 am ET
(6:30 am PT)
2017 Disruptive Growth & Healthcare
Conference
Date: Wednesday, February
15th
Location: Convene, New York
Presentation Time: 8:30 am ET
(5:30 am PT)
Small Cap Nation Family Office & Life Science
Symposium
Date: Tuesday, February
21st
Location: NASDAQ MarketSite, New
York
Presentation Time: 2:30 pm ET
(11:30 am PT)
RBC Capital Markets 2017 Global Healthcare Conference
Date: Wednesday, February 22nd
Location: Lotte New York Palace Hotel
Presentation Time: 8:00 am ET
(5:00 am PT)
Presentations will be webcast live and can be accessed through
the Investors page at www.acelrx.com. For those not available to
listen to the live broadcast, a replay will be archived for 90 days
and available through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx
Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on the development and commercialization of innovative therapies
for the treatment of moderate-to-severe acute pain. An NDA for
DSUVIA™ (sufentanil sublingual tablet, 30 mcg), known as
ARX-04 outside the United States,
with a proposed indication for the treatment of moderate-to-severe
acute pain in medically supervised settings, was submitted to the
FDA for review in December 2016.
The Company's follow on product, ZALVISO® (sufentanil
sublingual tablet system), designed for the management of
moderate-to-severe acute pain in adult patients in the hospital
setting, is currently enrolling patients in a Phase 3 clinical
trial, IAP312. ZALVISO delivers 15 mcg sufentanil sublingually
through a non-invasive delivery route via a pre-programmed,
patient-controlled analgesia device. ZALVISO is approved in the EU
and is investigational and in late-stage development in the U.S.
Grunenthal Group holds the rights for ZALVISO in Europe, where a commercial launch has
begun.
For additional information about AcelRx's clinical programs,
please visit www.acelrx.com.
Forward-Looking Statements
This press release
contains forward-looking statements, including, but not limited to,
statements related to the process and timing of anticipated future
development of AcelRx's product candidates, DSUVIATM
(sufentanil sublingual tablet, 30 mcg), known as ARX-04 outside
the United States, and
ZALVISO® (sufentanil sublingual tablet system),
including U.S. Food and Drug Administration, or FDA, review of the
New Drug Application, or NDA, for DSUVIA; the potential approval of
the DSUVIA NDA by the FDA; the DSUVIA and ARX-04 clinical trial
results; AcelRx's pathway forward towards gaining approval of
ZALVISO in the U.S., including successful completion of the IAP312
clinical study for ZALVISO; and the therapeutic and commercial
potential of AcelRx's product candidates, including potential
market opportunities and market size for DSUVIA, ARX-04 and
ZALVISO. These forward-looking statements are based on AcelRx
Pharmaceuticals' current expectations and inherently involve
significant risks and uncertainties. AcelRx Pharmaceuticals' actual
results and timing of events could differ materially from those
anticipated in such forward-looking statements, and as a result of
these risks and uncertainties, which include, without limitation,
risks related to AcelRx Pharmaceuticals' DSUVIA and ARX-04
development programs, including the FDA review of the DSUVIA NDA
and the possibility that the FDA may dispute or interpret
differently clinical results obtained from the DSUVIA Phase 2 and 3
studies; the ZALVISO development program, including successful
completion of IAP312 and the resubmission of the ZALVISO NDA to the
FDA; any delays or inability to obtain and maintain regulatory
approval of its product candidates, including DSUVIA in
the United States, ARX-04 in
Europe and ZALVISO in the United States; the uncertain clinical
development process; the success, cost and timing of all
development activities and clinical trials; and other risks
detailed in the "Risk Factors" and elsewhere in AcelRx's U.S.
Securities and Exchange Commission filings and reports, including
its Quarterly Report on Form 10-Q filed with the SEC on
November 2, 2016. AcelRx undertakes
no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future
events or changes in its expectations.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-at-four-upcoming-investor-events-in-february-300402914.html
SOURCE AcelRx Pharmaceuticals, Inc.